Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Representative image of AI-enabled liver disease research, reflecting how insitro’s CTRO-1013 MASH candidate is being studied for anti-fibrotic signals beyond liver fat reduction.
Pharma & Biotech

insitro’s MASH candidate adds a fibrosis signal, but human proof remains the real test

AI met MASH fibrosis, but mouse data are only the first test. See why insitro’s CTRO-1013 signal matters now.

Read More
Representative image of RNAi drug discovery research in a biotechnology laboratory. City Therapeutics’ $99.5 million Series B financing puts next-generation RNA interference therapies, including CITY-FXI and CITY-RBP4, in sharper focus as the field expands beyond liver-targeted medicines.
Pharma & Biotech

City Therapeutics raises $99.5m as CITY-FXI and CITY-RBP4 head toward key tests

City Therapeutics has fresh capital, but RNAi’s next test is tissue delivery. See why CITY-FXI and CITY-RBP4 matter now.

Read More
Representative image: A pediatric neurology research setting highlights the clinical focus on tralesinidase alfa, enzyme replacement therapy, and long-term treatment advances for Sanfilippo syndrome type B.
Pharma & Biotech

Could Spruce Biosciences finally change the Sanfilippo syndrome type B treatment landscape?

Spruce Biosciences’ MPS IIIB data raise a pivotal question: can tralesinidase alfa turn biomarker gains into disease-changing therapy?

Read More
Representative image of biopharma laboratory research. Gilead Sciences and Merck’s latest Phase 3 updates highlight the promise of once-weekly HIV treatment with islatravir and lenacapavir, while raising fresh questions over Trodelvy’s lung cancer expansion strategy.
Pharma & Biotech

Gilead and Merck pipeline update reveals promise in HIV and pressure in oncology

Gilead and Merck gain HIV momentum but face fresh oncology questions. See why this split pipeline update matters.

Read More
Representative image of cervical cancer treatment planning as Zai Lab’s TIVDAK approval expands China’s options for recurrent or metastatic disease.
Pharma & Biotech

TIVDAK approval gives Zai Lab a sharper China oncology story, but execution risk remains

TIVDAK enters China’s cervical cancer market with survival data. See why Zai Lab’s ADC approval matters beyond oncology headlines.

Read More
Pharma & Biotech

Why FDA approval for Hepcludex changes the treatment landscape for hepatitis delta virus

Find out how FDA approval for Gilead Sciences’ Hepcludex could reshape chronic hepatitis delta virus treatment in the U.S.

Read More
Representative image: A surgical team prepares a preserved donor heart in a high-tech transplant setting, reflecting the clinical and regulatory stakes behind United Therapeutics Corporation’s FDA-cleared UHeart xenotransplantation trial for end-stage heart failure.
Pharma & Biotech

Why United Therapeutics’ FDA-cleared UHeart trial could redefine xenotransplantation risk

Find out how United Therapeutics’ FDA-cleared UHeart trial could reshape xenotransplantation for end-stage heart failure patients.

Read More
Representative image of a rare disease neurology consultation, illustrating how Sanofi’s venglustat FDA priority review could change treatment options for type 3 Gaucher disease.
Pharma & Biotech

Can Sanofi’s venglustat priority review change the treatment outlook for type 3 Gaucher disease?

Sanofi’s venglustat could target neurological type 3 Gaucher disease. The FDA review now tests whether rare disease care can shift.

Read More
Representative image of an oncology consultation, illustrating how Roche and Genentech’s giredestrant FDA priority review could reshape endocrine therapy decisions in early-stage breast cancer.
Pharma & Biotech

Roche’s giredestrant FDA review raises the stakes in adjuvant breast cancer treatment

Find out how Roche’s giredestrant FDA priority review could reshape endocrine therapy in early breast cancer.

Read More
Representative image of a pediatric therapy consultation, illustrating how Biogen’s salanersen breakthrough therapy designation could shape the next phase of spinal muscular atrophy treatment and rare neurology care.
Pharma & Biotech

Can salanersen help Biogen defend its rare neurology franchise beyond Spinraza?

Find out how Biogen’s salanersen could reshape spinal muscular atrophy treatment after FDA breakthrough therapy status.

Read More